VESPER-2 VESPER-2 was a randomized, multicenter, double-blind, 28-week placebo-controlled trial that investigated the efficacy and safety of weekly berobenatide doses in adults with obesity or overweight and type 2 diabetes
Retatrutide is Eli Lilly and Company investigational next-generation obesity drug, designed to act on three signals in the body connected to appetite, fullness, blood sugar and energy use: GLP-1, GIP and glucagon
This hypothesis is further supported by clinical observations that more than 60% of accumulated fatty acids in the liver are derived from the circulation in NAFLD patients 7,8
Food and Drug Administration (FDA) updated the Ozempic label to include a warning for intestinal blockage after a growing number of post-marketing reports linked GLP-1 receptor agonists to severe gastrointestinal complications
Using it How do I reconstitute KLOW
75-LB: CT-388, A novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults
